Small Molecule · CT1812

Zervimesine

Phase 2Cognition Therapeutics, Inc. (CGTX)
  • FDA Fast Track (Mild-To-Moderate Alzheimer'S Disease; Granted October 2017)

Oral, once-daily, brain-penetrant small-molecule allosteric antagonist (modulator) of the sigma-2 receptor complex (TMEM97, with the PGRMC1 subunit as the described binding site), in development by Cognition Therapeutics for Alzheimer's disease and dementia with Lewy bodies. By binding the sigma-2 receptor complex at neuronal synapses it displaces amyloid-beta oligomers from their synaptic receptors — displaced oligomers are cleared into the CSF (shown directly in the Phase 1 SNAP catheter study) — and is hypothesized to protect synapses against both amyloid-beta and alpha-synuclein oligomer toxicity. Granted FDA Fast Track designation for mild-to-moderate Alzheimer's disease in October 2017. Clinical development has been funded by approximately $171 million in cumulative grants, primarily from the National Institute on Aging (NIA), including an ~$81 million NIA grant for the Phase 2 START study run with the Alzheimer's Clinical Trials Consortium (ACTC). Phase 2 results: SHINE (mild-to-moderate AD) reported a 95% slowing of ADAS-Cog 11 decline in the pre-specified below-median plasma p-tau217 subgroup; SHIMMER (DLB) showed benefits across behavioral, cognitive, functional and motor measures. FDA has aligned on registrational paths in both AD (two six-month Phase 3 studies, p-tau217-enriched) and DLB psychosis (nine-month pivotal). As of October 2025, ~782 subjects had received zervimesine across the clinical program, with the drug generally well tolerated.

Also known as: CT1812, CT-1812, CT 1812, zervimesine, Elayta, 1802632-22-9, 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol

Data current as of

Key facts

Modality
Small molecule
Chemical class
isoindoline, phenol, sulfone
Chemistry
Achiral
Mechanism
σ2 receptor (TMEM97) antagonist
Highest phase
Phase 2
Lead indication
Alzheimer's disease
Developer
Cognition Therapeutics, Inc. (CGTX)
Designations
FDA Fast Track (Mild-To-Moderate Alzheimer'S Disease; Granted October 2017)
Trials
5 tracked · 118 sites
Next catalyst
Mid-2027 (registry estimate May 2027) — Topline data (Alzheimer's disease)

Mechanism of action#

Orally bioavailable, brain-penetrant allosteric antagonist of the sigma-2 receptor complex — the transmembrane protein TMEM97 operating in a complex with progesterone receptor membrane component 1 (PGRMC1), which GtoPdb describes as zervimesine's binding subunit. The sigma-2 receptor complex regulates the synaptic receptors to which amyloid-beta oligomers bind; zervimesine binding increases the oligomer off-rate, displacing amyloid-beta oligomers from synapses into the CSF. This was demonstrated in humans in the Phase 1 SNAP study, where treated mild-to-moderate AD patients showed increased amyloid-beta oligomer concentrations in serially sampled CSF, confirming the preclinical displacement mechanism. Supporting synaptic evidence: improvement in prespecified qEEG parameters (SEQUEL) and reduced loss of brain volume in hippocampus, prefrontal and pericentral cortex on volumetric MRI (SPARC program imaging). In DLB the same synaptoprotective mechanism is hypothesized against alpha-synuclein oligomer toxicity. Selectivity is reported in reviews as roughly 100-fold over non-sigma receptors; no absolute Ki for CT1812 at the sigma-2 site is citable from an open source.

TargetActionAffinity
σ2 receptor (TMEM97)primaryTMEM97Antagonist—ⓘ
PGRMC1PGRMC1Antagonist—ⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
Zervimesine oral capsule (100 mg / 300 mg once daily)
100 mg or 300 mg once daily in the Phase 2 SHIMMER (DLB) and SHINE (mild-to-moderate AD) studies; 100 mg once daily in the DLB expanded access program (COG1202) and in the FDA-aligned pivotal design for DLB psychosis (nine months) and the Phase 3 AD design (six months).
OralOnce daily—

Development timeline#

201620182020202220242026TodayPhase 11 Sept 2015 — phase change — First-in-human ascending-dose study of CT1812 in healthy volunteers (COG0101, NCT02570997) started September 2015 (registry month precision; day is a placeholder). Conducted in Australia; NIA-funded.Phase 1/231 Oct 2017 — Fast Track — FDA grants Fast Track designation to zervimesine (CT1812) for mild-to-moderate Alzheimer's disease1 Sept 2016 — phase change — First-in-patient study in mild-to-moderate Alzheimer's disease (COG0102, NCT02907567, n=19) started September 2016 (registry month precision; day is a placeholder).Phase 231 May 2027 — upcoming — Topline results from the ~540-patient Phase 2 START study of zervimesine in MCI/early Alzheimer's disease (18-month treatment; CDR-SB and ADAS-Cog endpoints), expected after all participants complete 18 months of treatment — around mid-2027 per the ClinicalTrials.gov estimated primary completion of May 2027.24 Jun 2026 — phase change — Program active and pointed at a registrational path in DLB PSYCHOSIS: following a January 2026 Type C meeting, the 2026-03-02 decision to develop zervimesine for DLB psychosis, and a 2026-05-20 meeting with the FDA Division of Psychiatry, Cognition announced on 2026-06-24 (on receipt of meeting minutes) alignment with FDA on key aspects of a pivotal study — nine-month randomized Phase 3, 100 mg once daily vs placebo, in DLB patients with hallucinations and delusions (stable off-label antipsychotics allowed), NPI as a novel primary endpoint — and FDA agreement that DLB psychosis could be an approvable indication. Registrational program expected to begin mid-2027. Phase not advanced: no pivotal trial is registered or started. (No event logged: the closed vocabulary has no code for a regulatory meeting/alignment.)1 Dec 2025 — Conference presentation — Phase 3 plan for zervimesine in Alzheimer's disease presented at CTAD 202513 Nov 2025 — phase change — Enrollment completed in the ~540-patient Phase 2 START study (COG0203, NCT05531656) in MCI/early AD per the company's 2025-11-13 announcement (the FY2025 10-K states the last participant was enrolled in December 2025 — the PR date is used here and the discrepancy noted). FDA alignment on a Phase 3 AD registrational path was already in hand (end-of-Phase 2 minutes received 2025-08-12), but no Phase 3 study has been registered or started, so the phase does not advance.13 Nov 2025 — Enrollment complete — Enrollment completed in the Phase 2 START study of zervimesine in early Alzheimer's disease29 Jul 2025 — readout (met) — Full SHIMMER results presented in an AAIC 2025 podium presentation (with additional analyses spanning DLB and AD) and published in Alzheimer's & Dementia (Galvin et al. 2025): consistent benefit of zervimesine over placebo across neuropsychiatric, cognitive, motor and functional domains in mild-to-moderate DLB.29 Jul 2025 — Conference presentation — SHIMMER DLB data featured in podium presentation at AAIC 202518 Dec 2024 — readout (met) — Phase 2 SHIMMER topline (130 mild-to-moderate DLB patients, zervimesine 100/300 mg vs placebo, 6 months): primary safety/tolerability endpoint met, with exploratory efficacy signals across behavioral (NPI-12 -82% vs placebo decline), cognitive-fluctuation (CAF -91%), motor (UPDRS-III -62%) and functional (ADCS-ADL -52%) measures.25 Nov 2024 — phase change — SHIMMER completed per ClinicalTrials.gov (primary completion and study completion 2024-11-25); the company announced all participants had completed final visits on 2024-11-26, with topline following on 2024-12-18.31 Oct 2024 — readout (met) — Pre-specified analysis of SHINE presented at CTAD (October 2024): mild-to-moderate AD participants with baseline plasma p-tau217 below the 1.0 pg/mL median treated with zervimesine (pooled 100/300 mg) showed a 95% reduction of cognitive decline at week 26 on ADAS-Cog 11 vs placebo, regardless of MMSE stratum — the analysis that defined the p-tau217 enrichment strategy FDA later endorsed for Phase 3.29 Jul 2024 — readout (mixed) — Phase 2 SHINE topline (153 mild-to-moderate AD patients, zervimesine 100/300 mg vs placebo, 6 months): primary safety/tolerability endpoints met; cognitive signal favoring zervimesine, with the strongest effect emerging in patients with lower baseline plasma p-tau217.19 May 2022 — phase change — Phase 2 SHIMMER study (COG1201, NCT05225415) started per ClinicalTrials.gov: randomized, double-blind, placebo-controlled study of zervimesine 100 mg or 300 mg vs placebo once daily for six months in 130 adults with mild-to-moderate dementia with Lewy bodies. Funded primarily by an NIA grant (~$29.5M, awarded 2021).10 Oct 2018 — phase change — Phase 2 SHINE study (COG0201, NCT03507790) started: randomized, double-blind, placebo-controlled, 153 adults with mild-to-moderate AD, zervimesine 100 mg or 300 mg vs placebo once daily for six months. NIA-funded ($16.8M initial + $13.6M 2021 amendment).
Phase change Readout Event UpcomingHover a marker for details.
Phase 2Oct 2018 – May 2027
  1. UpcomingTopline results from the ~540-patient Phase 2 START study of zervimesine in MCI/early Alzheimer's disease (18-month treatment; CDR-SB and ADAS-Cog endpoints), expected after all participants complete 18 months of treatment — around mid-2027 per the ClinicalTrials.gov estimated primary completion of May 2027.Alzheimer's disease↗
  2. Program active and pointed at a registrational path in DLB PSYCHOSIS: following a January 2026 Type C meeting, the 2026-03-02 decision to develop zervimesine for DLB psychosis, and a 2026-05-20 meeting with the FDA Division of Psychiatry, Cognition announced on 2026-06-24 (on receipt of meeting minutes) alignment with FDA on key aspects of a pivotal study — nine-month randomized Phase 3, 100 mg once daily vs placebo, in DLB patients with hallucinations and delusions (stable off-label antipsychotics allowed), NPI as a novel primary endpoint — and FDA agreement that DLB psychosis could be an approvable indication. Registrational program expected to begin mid-2027. Phase not advanced: no pivotal trial is registered or started. (No event logged: the closed vocabulary has no code for a regulatory meeting/alignment.)Lewy body dementia↗
  3. Conference presentationPhase 3 plan for zervimesine in Alzheimer's disease presented at CTAD 2025Alzheimer's disease↗
  4. Enrollment completed in the ~540-patient Phase 2 START study (COG0203, NCT05531656) in MCI/early AD per the company's 2025-11-13 announcement (the FY2025 10-K states the last participant was enrolled in December 2025 — the PR date is used here and the discrepancy noted). FDA alignment on a Phase 3 AD registrational path was already in hand (end-of-Phase 2 minutes received 2025-08-12), but no Phase 3 study has been registered or started, so the phase does not advance.Alzheimer's disease↗
  5. Enrollment completeEnrollment completed in the Phase 2 START study of zervimesine in early Alzheimer's diseaseAlzheimer's disease↗
  6. metFull SHIMMER results presented in an AAIC 2025 podium presentation (with additional analyses spanning DLB and AD) and published in Alzheimer's & Dementia (Galvin et al. 2025): consistent benefit of zervimesine over placebo across neuropsychiatric, cognitive, motor and functional domains in mild-to-moderate DLB.Lewy body dementia↗
  7. Conference presentationSHIMMER DLB data featured in podium presentation at AAIC 2025Lewy body dementia↗
  8. metPhase 2 SHIMMER topline (130 mild-to-moderate DLB patients, zervimesine 100/300 mg vs placebo, 6 months): primary safety/tolerability endpoint met, with exploratory efficacy signals across behavioral (NPI-12 -82% vs placebo decline), cognitive-fluctuation (CAF -91%), motor (UPDRS-III -62%) and functional (ADCS-ADL -52%) measures.Lewy body dementia↗
  9. SHIMMER completed per ClinicalTrials.gov (primary completion and study completion 2024-11-25); the company announced all participants had completed final visits on 2024-11-26, with topline following on 2024-12-18.Lewy body dementia
  10. metPre-specified analysis of SHINE presented at CTAD (October 2024): mild-to-moderate AD participants with baseline plasma p-tau217 below the 1.0 pg/mL median treated with zervimesine (pooled 100/300 mg) showed a 95% reduction of cognitive decline at week 26 on ADAS-Cog 11 vs placebo, regardless of MMSE stratum — the analysis that defined the p-tau217 enrichment strategy FDA later endorsed for Phase 3.Alzheimer's disease↗
  11. mixedPhase 2 SHINE topline (153 mild-to-moderate AD patients, zervimesine 100/300 mg vs placebo, 6 months): primary safety/tolerability endpoints met; cognitive signal favoring zervimesine, with the strongest effect emerging in patients with lower baseline plasma p-tau217.Alzheimer's disease↗
  12. Phase 2 SHIMMER study (COG1201, NCT05225415) started per ClinicalTrials.gov: randomized, double-blind, placebo-controlled study of zervimesine 100 mg or 300 mg vs placebo once daily for six months in 130 adults with mild-to-moderate dementia with Lewy bodies. Funded primarily by an NIA grant (~$29.5M, awarded 2021).Lewy body dementia
  13. Phase 2 SHINE study (COG0201, NCT03507790) started: randomized, double-blind, placebo-controlled, 153 adults with mild-to-moderate AD, zervimesine 100 mg or 300 mg vs placebo once daily for six months. NIA-funded ($16.8M initial + $13.6M 2021 amendment).Alzheimer's disease
Phase 1/2Sept 2016 – Oct 2017
  1. Fast TrackFDA grants Fast Track designation to zervimesine (CT1812) for mild-to-moderate Alzheimer's diseaseAlzheimer's disease↗
  2. First-in-patient study in mild-to-moderate Alzheimer's disease (COG0102, NCT02907567, n=19) started September 2016 (registry month precision; day is a placeholder).Alzheimer's disease
Phase 1Sept 2015
  1. First-in-human ascending-dose study of CT1812 in healthy volunteers (COG0101, NCT02570997) started September 2015 (registry month precision; day is a placeholder). Conducted in Australia; NIA-funded.Alzheimer's disease

Zervimesine for Alzheimer's disease#

Phase 2ActiveAlzheimer's disease indication →

Zervimesine (CT1812), an oral once-daily sigma-2 receptor complex allosteric antagonist, for Alzheimer's disease — Cognition Therapeutics' lead indication, funded primarily by NIA grants (~$171M cumulative across the program). Completed Phase 2 evidence: the 153-patient SHINE study (mild-to-moderate AD, 100/300 mg vs placebo for 6 months; NIA-funded ~$30M with amendment) met its safety/tolerability primary endpoints and, in a pre-specified analysis reported at CTAD in October 2024, showed a 95% slowing of ADAS-Cog 11 decline at week 26 in participants with baseline plasma p-tau217 below the 1.0 pg/mL median (pooled doses vs placebo); the 16-patient SEQUEL qEEG study showed improvement in prespecified EEG parameters. Ongoing: the ~540-patient Phase 2 START study (COG0203, NCT05531656) in MCI/early AD, run with the NIA-funded Alzheimer's Clinical Trials Consortium under an ~$81M NIA grant — 18 months of treatment, CDR-SB and ADAS-Cog endpoints; enrollment completed November–December 2025, with topline expected after all participants complete 18 months of treatment (registry-estimated primary completion May 2027). Regulatory: end-of-Phase 2 meeting held 2025-07-09; minutes received 2025-08-12 confirmed FDA alignment that two six-month Phase 3 studies of 100 mg zervimesine vs placebo in mild-to-moderate AD patients enriched for lower plasma p-tau217 may support an NDA filing; the Phase 3 plan (iADRS primary) was presented at CTAD on 2025-12-01. EMA scientific advice (per the FY2025 10-K) indicated a preference for a longer trial than proposed, and no Phase 3 study has been registered or started, so the program remains recorded at Phase 2.

Readouts

  • Mid-2027 (registry estimate May 2027)AnticipatedTopline dataNCT05531656

    Topline results from the ~540-patient Phase 2 START study of zervimesine in MCI/early Alzheimer's disease (18-month treatment; CDR-SB and ADAS-Cog endpoints), expected after all participants complete 18 months of treatment — around mid-2027 per the ClinicalTrials.gov estimated primary completion of May 2027. ↗

  • 2024-10-31ReportedFull resultsmetNCT03507790

    Pre-specified analysis of SHINE presented at CTAD (October 2024): mild-to-moderate AD participants with baseline plasma p-tau217 below the 1.0 pg/mL median treated with zervimesine (pooled 100/300 mg) showed a 95% reduction of cognitive decline at week 26 on ADAS-Cog 11 vs placebo, regardless of MMSE stratum — the analysis that defined the p-tau217 enrichment strategy FDA later endorsed for Phase 3. ↗

  • 2024-07-29ReportedTopline datamixedNCT03507790

    Phase 2 SHINE topline (153 mild-to-moderate AD patients, zervimesine 100/300 mg vs placebo, 6 months): primary safety/tolerability endpoints met; cognitive signal favoring zervimesine, with the strongest effect emerging in patients with lower baseline plasma p-tau217. ↗

Zervimesine for Lewy body dementia#

Phase 2ActiveLewy body dementia indication →

Zervimesine (CT1812), an oral once-daily sigma-2 receptor complex allosteric antagonist, for dementia with Lewy bodies — now being steered specifically toward DLB psychosis, which affects up to ~75% of DLB patients and has no FDA-approved treatment. The completed Phase 2 SHIMMER study (COG1201, NCT05225415; 130 patients with mild-to-moderate DLB, zervimesine 100 or 300 mg vs placebo for six months; NIA-funded, ~$29.5M) met its primary safety/tolerability endpoint (topline 2024-12-18) and showed consistent exploratory efficacy signals vs placebo: 82% slowing of neuropsychiatric symptom progression (NPI-12, strongest on anxiety, hallucinations and delusions), 91% on cognitive fluctuations (CAF), 62% on parkinsonian motor decline (UPDRS-III) and 52% on activities of daily living (ADCS-ADL). Full results were presented in an AAIC podium presentation (2025-07-29) and published in Alzheimer's & Dementia (Galvin et al. 2025). An open-label expanded access program (COG1202, NCT06961760; 100 mg daily for ~1 year) enrolled 32 SHIMMER completers and additional mild-to-moderate DLB patients between June and December 2025 and was extended in February 2026. Regulatory path: after a January 2026 FDA Type C meeting, Cognition announced (2026-03-02) it would develop zervimesine for DLB psychosis; a 2026-05-20 meeting with the FDA Division of Psychiatry and the minutes received by 2026-06-24 aligned on key aspects of a pivotal design — a randomized Phase 3 of 100 mg once-daily zervimesine vs placebo over nine months in DLB patients experiencing hallucinations and delusions (patients on stable off-label antipsychotics eligible), with the Neuropsychiatric Inventory (NPI) as a novel primary endpoint — and the FDA agreed DLB psychosis could be an approvable indication. The registrational program is expected to begin in mid-2027; the program stays at Phase 2 until that pivotal is registered or started.

Readouts

  • 2025-07-29ReportedFull resultsmetNCT05225415

    Full SHIMMER results presented in an AAIC 2025 podium presentation (with additional analyses spanning DLB and AD) and published in Alzheimer's & Dementia (Galvin et al. 2025): consistent benefit of zervimesine over placebo across neuropsychiatric, cognitive, motor and functional domains in mild-to-moderate DLB. ↗

  • 2024-12-18ReportedTopline datametNCT05225415

    Phase 2 SHIMMER topline (130 mild-to-moderate DLB patients, zervimesine 100/300 mg vs placebo, 6 months): primary safety/tolerability endpoint met, with exploratory efficacy signals across behavioral (NPI-12 -82% vs placebo decline), cognitive-fluctuation (CAF -91%), motor (UPDRS-III -62%) and functional (ADCS-ADL -52%) measures. ↗

Clinical trials#

NCT05531656COG0203Phase 2Activen=540

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease (START)

Started Jun 2023· Primary completion May 2027· 50 sites across 1 country

United States

NCT05225415COG1201Phase 2Completedn=130

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies (SHIMMER)

Started May 2022· Primary completion Nov 2024· 34 sites across 1 country

United States

NCT04735536COG0202Phase 2Completedn=16

Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG (SEQUEL)

Started Jul 2020· Primary completion Apr 2023· 1 site across 1 country

Netherlands

NCT03507790COG0201Phase 2Completedn=153

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease (SHINE)

Started Oct 2018· Primary completion May 2024· 32 sites across 5 countries

United StatesCzechiaSpainAustralia

NCT03493282COG0105Phase 1/2Completedn=43

Effect of CT1812 Treatment on Brain Synaptic Density (SPARC)

Started Mar 2018· Primary completion Oct 2020· 1 site across 1 country

United States

Sources#

  1. Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes (2026-06-24; registrational program expected to begin mid-2027) — Cognition Therapeutics, Inc. (via GlobeNewswire)
  2. Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies (2024-12-18, SHIMMER topline) — Cognition Therapeutics, Inc. (via GlobeNewswire)
  3. Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD (October 2024) — Cognition Therapeutics, Inc.
  4. Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease (2025-11-13) — Cognition Therapeutics, Inc. (via GlobeNewswire)
  5. Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease (2025-07-29) — Cognition Therapeutics, Inc. (via GlobeNewswire)
  6. Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference (2025-12-01) — Cognition Therapeutics, Inc.
  7. Cognition Therapeutics, Inc. Form 10-K for fiscal year 2024 — SHINE topline conference call held July 29, 2024; p-tau217 subgroup analysis — U.S. Securities and Exchange Commission (EDGAR)
  8. Cognition Therapeutics, Inc. Form 10-K for fiscal year 2025 (filed 2026-03-26) — SHIMMER NIA grant ($29.5M); SHIMMER effect sizes; COG1202 EAP (32 enrolled, June–December 2025, 100 mg daily ~1 year); January 2026 Type C meeting and DLB-psychosis strategy; corporate facts — U.S. Securities and Exchange Commission (EDGAR)
  9. CT1812 (zervimesine), GtoPdb ligand 13335 — orally bioactive, brain-penetrant sigma-2 receptor complex allosteric antagonist binding at the PGRMC1 subunit; displaces amyloid-beta for disposal via CSF — IUPHAR/BPS Guide to PHARMACOLOGY
  10. NCT02570997 (COG0101) — Ascending Dose Study of CT1812 in Healthy Volunteers; started September 2015; completed — ClinicalTrials.gov (U.S. National Library of Medicine)
Show all 16 sources
  1. NCT02907567 (COG0102) — Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease; started September 2016; completed — ClinicalTrials.gov (U.S. National Library of Medicine)
  2. NCT03493282 (COG0105, SPARC) — Effect of CT1812 Treatment on Brain Synaptic Density; completed — ClinicalTrials.gov (U.S. National Library of Medicine)
  3. NCT03507790 (COG0201, SHINE) — A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease; 153 participants; completed 2024-05-29 — ClinicalTrials.gov (U.S. National Library of Medicine)
  4. NCT04735536 (COG0202, SEQUEL) — Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG; completed — ClinicalTrials.gov (U.S. National Library of Medicine)
  5. NCT05225415 (COG1201, SHIMMER) — Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies; 130 participants; completed 2024-11-25 — ClinicalTrials.gov (U.S. National Library of Medicine)
  6. NCT05531656 (COG0203, START) — A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease; 540 participants; active, not recruiting; est. primary completion 2027-05-31 — ClinicalTrials.gov (U.S. National Library of Medicine)